These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31808835)

  • 21. Reversal agents for oral anticoagulant-associated major or life-threatening bleeding.
    Moia M; Squizzato A
    Intern Emerg Med; 2019 Nov; 14(8):1233-1239. PubMed ID: 31446606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants.
    Dager W; Hellwig T
    Am J Health Syst Pharm; 2016 May; 73(10 Suppl 2):S14-26. PubMed ID: 27147455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018.
    Gibler WB; Racadio JM; Hirsch AL; Roat TW
    Crit Pathw Cardiol; 2019 Sep; 18(3):143-166. PubMed ID: 31348075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma.
    Wienhold J; Rayatdoost F; Schöchl H; Grottke O
    Curr Opin Anaesthesiol; 2024 Apr; 37(2):101-109. PubMed ID: 38390922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct oral anticoagulants: a review on the current role and scope of reversal agents.
    Chaudhary R; Sharma T; Garg J; Sukhi A; Bliden K; Tantry U; Turagam M; Lakkireddy D; Gurbel P
    J Thromb Thrombolysis; 2020 Feb; 49(2):271-286. PubMed ID: 31512202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Historical Perspective on the Reversal of Anticoagulants.
    Salter B; Crowther M
    Semin Thromb Hemost; 2022 Nov; 48(8):955-970. PubMed ID: 36055273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and effectiveness of Factor Eight Inhibitor Bypassing Activity for direct oral anticoagulant-related hemorrhage reversal.
    Engelbart JM; Zepeski A; Galet C; Policeni B; Skeete DA; Faine BA
    Am J Emerg Med; 2019 Feb; 37(2):214-219. PubMed ID: 29802004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature.
    Shaw JR; Castellucci LA; Siegal D; Carrier M
    J Thromb Haemost; 2023 Mar; 21(3):433-452. PubMed ID: 36696204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of hemorrhage in patients treated with direct oral anticoagulants].
    Grottke O; Lier H; Hofer S
    Anaesthesist; 2017 Sep; 66(9):679-689. PubMed ID: 28455651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haematological management of major bleeding associated with direct oral anticoagulants - UK experience.
    Green L; Tan J; Antoniou S; Alikhan R; Curry N; Everington T; Saja K; Stanworth S; Tait C; Morris JK; MacCallum P
    Br J Haematol; 2019 May; 185(3):514-522. PubMed ID: 30784047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on the bleeding risks associated with DOACs.
    Drug Ther Bull; 2017 Nov; 55(11):129-132. PubMed ID: 29117993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of direct oral anticoagulant therapy reversal.
    Gulseth MP
    Am J Health Syst Pharm; 2016 May; 73(10 Suppl 2):S5-S13. PubMed ID: 27147458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to effectively manage the event of bleeding complications when using anticoagulants.
    Sartori MT; Prandoni P
    Expert Rev Hematol; 2016 Jan; 9(1):37-50. PubMed ID: 26573697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants.
    Dager WE; Roberts AJ; Nishijima DK
    Thromb Res; 2019 Jan; 173():71-76. PubMed ID: 30476716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
    Enríquez A; Baranchuk A; Corbalán R
    Rev Med Chil; 2019; 147(1):73-82. PubMed ID: 30848768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current evidence of oral anticoagulant reversal: A systematic review.
    Tornkvist M; Smith JG; Labaf A
    Thromb Res; 2018 Feb; 162():22-31. PubMed ID: 29258056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants.
    Summers RL; Sterling SA
    Air Med J; 2016; 35(3):148-55. PubMed ID: 27255877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific antidotes in development for reversal of novel anticoagulants: a review.
    Gomez-Outes A; Suarez-Gea ML; Lecumberri R; Terleira-Fernandez AI; Vargas-Castrillon E
    Recent Pat Cardiovasc Drug Discov; 2014; 9(1):2-10. PubMed ID: 25494843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.